|

A Long-Term Follow-Up Study of Participants Exposed to REACT

RECRUITINGSponsored by Prokidney
Actively Recruiting
SponsorProkidney
Started2023-12-11
Est. completion2028-01
Eligibility
Age30 Years – 80 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT05918523

Summary

The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).

Eligibility

Age: 30 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.

Exclusion Criteria:

* The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.

Conditions3

Chronic Kidney DiseasesDiabetesDiabetic Kidney Disease

Locations1 site

Boise Kidney & Hypertension Institute
Meridian, Idaho, 83642
Arnold Silva, MD

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.